Biocartis announced the launch of two new products on its molecular diagnostics platform Idylla™. The Idylla™ ctBRAF Mutation Assay uses blood plasma as a sample, which is far less invasive to obtain compared to tissue biopsies. As plasma samples can repeatedly be obtained and do not require prior information on the tumour location, liquid biopsy testing opens up a range of new possibilities in terms of efficient cancer monitoring and treatment. The second assay launched by Biocartis is the tissue biopsy Idylla™ NRAS-BRAF-EGFR S492R Mutation Assay. This assay now allows Biocartis to offer a complete RAS-BRAF analysis that can be performed on a same-day basis, which opens up the route towards faster treatment selection (‘same day results’). Both assays are initially launched as Research Use Only (RUO) products.
Source: Biocartis